Pharma Focus Europe

Acquisition of Argatroban Business in Europe

Monday, June 17, 2024

Ethypharm has entered into an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) to acquire the selective antithrombin agent Argatroban monohydrate (marketed under various brands including Argatra®, Arganova®, Novastan®, Exembol®) for distribution in Europe.

Known for its expertise in essential drugs for central nervous system diseases, severe pain, addiction treatments, and hospital injectables, Ethypharm aims to bolster its pharmaceutical business in Europe through internal development, licensing, and strategic acquisitions.

MTPC first obtained approval for Argatroban in Sweden in 2004, and it is currently available in 13 European countries, including Germany, the UK, France, Spain, and Italy, for treating heparin-induced thrombocytopenia (HIT) type II—a severe condition associated with potentially fatal thromboembolic complications. Argatroban, characterized by its short half-life and hepatic metabolism, is particularly suitable for patients post-surgery and those with kidney disease at risk of developing HIT type II.

Denis Delval, CEO of Ethypharm, stated, "We are pleased to expand our portfolio of essential medications and introduce Argatroban to patients across Europe. We are proud to continue the legacy of this product following its development by the reputable Mitsubishi Tanabe Pharma Corporation."



Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024